Dianthus Therapeutics is positioned as a category-expanding biotech, leveraging convenience and safety. Find out why DNTH stock is a buy.

With this blooming perennial, you get a vibrant flower that smells delightful and attracts butterflies. It's ideal for a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

On May 7, Raymond James increased its price target on Dianthus Therapeutics Inc. (NASDAQ:DNTH) from $123 to $125.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Develops monoclonal antibody therapeutics, with its lead candidate, DNTH103, targeting severe autoimmune and inflammatory diseases and in phase 1 clinical trials. Operates a clinical-stage ...

Dianthus Therapeutics’ claseprubart has met its primary and secondary endpoints during a Phase II trial in generalised myasthenia gravis (gMG). During the MaGic study (NCT06282159), the active ...

References to the plant genus Dianthus go back as far as the Greek botanist Theophrastus. He named these plants from the Caryophyllaceae family “divine flower” (dios = divine plus anthos = flower).

Octagon Capital Advisors sold 470,000 shares of Dianthus Therapeutics in the first quarter; the estimated transaction value was $27.22 million (based on quarterly average prices). The quarter-end ...

Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today ...